Richard Gawel

SAN DIEGO — Patients with food allergy in vulnerable communities experience significant disparities in diagnosis and management, including food insecurity, according to a pair of posters presented here. Improved access to care and resources would benefit these communities, Anita Roach, MS, vice president of health equity and community, Food Allergy Research & Education (FARE), said at

SAN DIEGO — Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV Technologies increased from 12 months through 60 months, according to an abstract presented here. Treatment also was well tolerated, David Fleischer, MD, FAAAAI, section head of allergy and immunology, Children’s Hospital Colorado, said at the 2025 American

SAN DIEGO — Patients with three different food allergies who used omalizumab experienced better outcomes than patients who used multi-food oral immunotherapy, driven by lower rates of adverse events, according to an abstract presented here. Robert A. Wood, MD, FAAAAI, professor of pediatrics, Johns Hopkins University School of Medicine, led the study, presented at the 2025 American

Families, physicians and other stakeholders will be in Washington, D.C., to meet with legislators and advocate for change on Wednesday, May 7, as part of Allergy & Asthma Day Capitol Hill. Sponsored by Allergy & Asthma Network, the 28th annual event will connect patients with their representatives in the House and Senate.

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert A. Wood, MD, FAAAAI, professor of pediatrics, Johns Hopkins University School of Medicine, told Healio. “It’s been a very exciting year in the world of food allergy,” said Wood, who also was the lead author of the phase 3 Omalizumab as

The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with two cartons of the company’s neffy epinephrine nasal spray, including a total of four single-use doses, for free. Schools can use these 2 mg doses of neffy to treat anaphylaxis and other type 1 allergic reactions in adults and children who weigh 66 lbs or more. Once

Patients with food allergies face many risks when they dine and travel away from home, but doctors need data to help prioritize and address these dangers. The European Academy of Allergy and Clinical Immunology Food Allergy Ingestion Risk (EAACI FAIR) Taskforce has launched a pair of online international surveys to gather this information directly from patients and their families.

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate to severe atopic dermatitis that topical therapies have not adequately controlled, according to a press release.As an investigational biologic therapy, Nektar Therapeutics said in the release, rezpegaldesleukin targets the IL-2 receptor complex to stimulate the

Dining out can be scary for the 33 million people in the United States with a food allergy. Even when restaurants list allergic ingredients in their menus, the information may be out of date or hard to find.EveryBite aims to change that dynamic. It is now working with 50 restaurant brands with more than 4,000 locations to implement its SmartMenu technology on their websites.

Patients with stroke and inaccurate NSAID allergy labels had poorer outcomes including major adverse cardiovascular events, peripheral vascular disease and death, according to a study published in Stroke.Multidisciplinary interventions may improve these outcomes, Philip Li Hei, MD, clinical assistant professor, department of medicine, School of Medicine, LKS Faculty of Medicine of the University